 The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer NSCLC. This study will be conducted in Asian patients who are classified as never smoker since it is suggested that these patients are more likely to respond favorably to treatment with gefitinib. 